Biodexa Pharmaceuticals (BDRX) has released an update.
Biodexa Pharmaceuticals PLC has announced the initiation of a Phase 2a study for tolimidone in the treatment of Type 1 diabetes, which has received approval from Health Canada. The study, in collaboration with the University of Alberta, will investigate the drug’s impact on insulin and blood glucose levels in patients. Tolimidone, previously developed by Pfizer for gastric ulcers but discontinued, is now being repurposed by Biodexa due to its potential to improve beta cell function in diabetes.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
